Understanding the Disposition of Lipid Nanoparticle (LNP) Formulations in NHP Models

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES.

Understanding the Disposition of Lipid Nanoparticle (LNP) Formulations in NHP Models

LNP Pharmacokinetics and Biodistribution

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions

    What is the primary goal of an LNP PK study?

    The objective is to characterize the absorption, distribution, metabolism, and excretion (ADME) of a lipid nanoparticle formulation. This data informs the design of IND-enabling toxicology studies and helps define the therapeutic window for RNA payloads.

    Why are nonhuman primate models selected for LNP biodistribution?

    Nonhuman primate models are selected for their immunological and physiological similarity to humans. This allows for a more predictive assessment of how an LNP formulation will behave in a clinical setting, particularly regarding organ-specific accumulation and potential off-target effects.

    How does helper lipid composition affect LNP targeting?

    The choice of helper lipid directly influences protein interactions in circulation. As shown in biodistribution studies, different helper lipids can promote preferential uptake in specific organs, such as the liver or spleen, by altering these interaction profiles (PMID: 33404020).


Additional Insights

Characterizing the disposition of lipid nanoparticle (LNP) formulations is a required step in the development of many Advanced Therapeutics and Complex Biologics. Applying proven intelligence in preclinical toxicology is how our scientific teams accelerate these next-generation therapies toward successful IND submissions. A standard preclinical template does not exist for these assets; each program requires a data-driven strategy tailored to the specific LNP composition and RNA payload.

The infrastructure required to support these programs must adapt to their complexity. “The value chain is diversifying… we are no longer just dealing with a pill in a bottle. We are dealing with living cells, with viral vectors, and the infrastructure has to adapt to that reality.” This is especially true for LNP systems, where minor formulation changes can produce significant shifts in biodistribution.

Scientific literature confirms that helper lipid structure is a key determinant of LNP delivery. Preclinical evaluations have shown that formulations containing certain helper lipids preferentially target the liver, while others direct the LNP to the spleen. This organ-specific tropism has direct implications for both efficacy and the design of subsequent toxicology programs.

A well-designed LNP pharmacokinetic study includes:

  • Selection of a nonhuman primate model with an immune system that closely mirrors the human response.
  • Quantification of the LNP and its payload in plasma and tissues, executed under phase-appropriate GCLP guidelines.
  • Comprehensive tissue collection protocols to accurately map biodistribution.
  • Execution within a GLP-compliant environment to support regulatory filings.

This detailed characterization provides the data necessary to de-risk clinical translation. Understanding where an LNP formulation accumulates allows sponsors to move forward with confidence, backed by a team whose work has resulted in a 100% successful IND rate since 2019. This legacy, now operating as Franklin Biolabs since our 2024 launch, continues to accelerate programs from candidate to IND within 18-24 months. For more information on our comprehensive support, please see our parent Preclinical | Translational Services hub.


Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.